NEW YORK (GenomeWeb News) – Beckman Coulter announced yesterday that Aviv Biomedical would sell and install its Fluorescence Detection System on Beckman Coulter’s ProteomeLab XL-A, XL-I analytical centrifuges currently in the field.
Beckman’s ProteomeLab instruments measure proteins and other macromolecules as interacting elements in solution instead of in isolation, diluted, or bound to a substrate.
The Fullerton, Calif.-based firm said that Aviv’s FDS offers a “complementary approach to measuring molecular interaction and aggregation behavior.” Using fluorescent labeling, the system enables researchers to validate lead drug efficacy by confirming that it binds only to a desired substrate and to other components, said Beckman.
While Lakewood, NJ-based Aviv will sell and install the FDS, Beckman said that it would validate the installation.
Financial and other terms of the alliance were not announced.